TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03931382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulator
Description: The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mock MRI Simulator
Description: The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation Manual
Description: The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
Study: NCT04975659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and Nocebo effect
Description: Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Nocebo effect
Description: Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
Study: NCT01819571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid loading (Voluven)
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
Study: NCT03419637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
Study: NCT04642118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver
Description: Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
Study: NCT03187795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
Study: NCT03960203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InSight
Description: Clinical decision support (CDS) system for severe sepsis detection and prediction
Study: NCT00867503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine HCL
Description: bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
Study: NCT00719030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate pill
Description: Pomegranate extract pill
Study: NCT05431231

Intervention type: DIAGNOSTIC_TEST
Intervention: Manchester Short Assessment of Quality
Description: a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
Study: NCT04642118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary recruitment maneuver
Description: Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
Study: NCT01062789

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical breath-hold control system (OBC)
Description: The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
Study: NCT01407952

Intervention type: DEVICE
Group type: OTHER
Intervention: HydroCoil Embolic System
Description: HydroCoil Embolic System

Intervention type: DEVICE
Group type: OTHER
Intervention: Control (bare platinum coils)
Description: bare platinum coils
Study: NCT01547351

Intervention type: OTHER
Intervention: ARMS Questionnaire
Description: The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
Study: NCT00719030

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pomegranate pill placebo
Description: Pomegranate pill placebo
Study: NCT01054235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
Study: NCT03865368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration Training
Description: Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
Study: NCT01724489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01059487

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Chinese Medicine
Description: Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
Study: NCT00872638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eversion
Description: Surgical incisions will be closed in such a manner so as to evert the wound edges.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approximation
Description: Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
Study: NCT02302053

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Viviscal Professional Supplement
Description: The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
Study: NCT02618135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
Study: NCT00977886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELB353
Description: Oral, 10 days
Study: NCT01517373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 10 mg
Description: Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 50 mg
Description: Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 100 mg
Description: Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
Study: NCT03323437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
Study: NCT01534351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5 mg oral tablet taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5 mg oral tablet taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin 0.2 mg oral capsule taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.2 mg oral capsule taken once daily.
Study: NCT02863055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 200 mg administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered twice daily
Study: NCT01534351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride-matching placebo
Description: Matching placebo to finasteride 5 mg oral tablet taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin-matching placebo
Description: Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
Study: NCT02182778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin /S-1
Description: S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
Study: NCT00566371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05431231

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-Stigma of Mental Illness Scale
Description: a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.

Intervention type: DIAGNOSTIC_TEST
Intervention: Session Alliance Inventory - for patient
Description: this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
Study: NCT04325711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA131
Description: CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
Study: NCT03367338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-phosphate diet
Description: Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-phosphate diet
Description: Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
Study: NCT04257487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: 2 soft capsules of Vessel® 250 LSU BID for 12 months
Study: NCT05431231

Intervention type: DIAGNOSTIC_TEST
Intervention: Session Alliance Inventory - for patient
Description: this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.

Intervention type: DIAGNOSTIC_TEST
Intervention: Session Alliance Inventory - for patient
Description: this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
Study: NCT04257487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide and placebo
Description: 1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic sulodexide 250 LSU
Study: NCT01206660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone Spray 0.25%
Description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered to affected area twice a day for 28 days
Study: NCT04767932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vibration machine
Description: Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
Study: NCT01811654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Hyaluronic Acid-Euflexxa
Description: IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
Study: NCT02575495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 days course of antibiotic treatment
Description: start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 days course of antibiotic treatment
Description: start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
Study: NCT03449563

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Open TPVB
Description: In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
Study: NCT05431231

Intervention type: OTHER
Intervention: Quality of service/satisfaction questionnaire
Description: measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.

Intervention type: OTHER
Intervention: Quality of service/satisfaction questionnaire
Description: measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.

Intervention type: OTHER
Intervention: Quality of service/satisfaction questionnaire
Description: measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical decision-making style
Description: a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical decision-making style
Description: a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.